| Identification | Back Directory | [Name]
SI-2 Hydrochloride | [CAS]
1992052-49-9 | [Synonyms]
SI-2 Hydrochloride
EPH 116 hydrochloride | [Molecular Formula]
C15H15N5·HCl | [MDL Number]
MFCD30290164 | [MOL File]
1992052-49-9.mol | [Molecular Weight]
301.78 |
| Hazard Information | Back Directory | [Uses]
SI-2 Hydrochloride is a useful intermediate. | [in vivo]
SI-2 causes minimal acute cardiotoxicity based on a hERG channel blocking assay and an unappreciable chronic toxicity to major organs based on histological analyses[1].
SI-2 is a drug-like molecule and meets all of the criteria of Lipinski’s rule[1].
| Animal Model: | MDA-MB-468 breast cancer mouse model[1].
| | Dosage: | 2 mg/kg. | | Administration: | Twice daily for 5 weeks (Vehicle, PBS). | | Result: | Significantly inhibit tumor growth.
SRC-3 levels in SI-2–treated tumor tissues were significantly lower than the PBS treated control group.
|
| Animal Model: | CD1 mice[1]. | | Dosage: | 20 mg/kg (Pharmacokinetic Analysis). | | Administration: | Intraperitoneal administration once. | | Result: | T1/2 = 1 h, Cmax of 3.0 μM, and the time to reach the maximum plasma concentration tmax of 0.25 h.
SI-2 only degrades slightly (less than 5%) at pH 1.6 and 3.0 within 6 h, and is stable in buffers with pH ≥ 5.
|
|
|
| Company Name: |
Bide Pharmatech Ltd.
|
| Telephone: |
400-1647117 13681763483 |
| Website: |
https://www.bidepharm.com/ |
|